Correction to: Belsey JD. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen. Curr Med Res Opin 2008;24:581–89.

The author has been made aware of several errors that appeared in his recent article and is happy to be able to make the following corrections:

1. In the first sentence of the first paragraph on page 586, incorrect values were quoted for the median costs of different treatment regimens. The corrected text should read:

   For both undiscounted and discounted models, losartan represents the least costly option at £536 and £506 median total cost per patient, versus £662 and £610 for candesartan, £754 and £696 for irbesartan, and £869 and £809 for valsartan.

2. In Table 1, the confidence intervals for DBP reduction for Irbesartan 150–300 mg from the analysis of Baguet et al. was misquoted. It should have read (10.0–11.4), not (10.0–11.3).

3. In Figure 5, the right-hand column pair should have been labelled Irbesartan, and not Irebesartan.

None of these changes will affect the conclusions drawn by the author.